Fig. 1: Best percentage change in tumor size from baseline and tumor response by LOH and TMB scores (modified full analysis set).
From: Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
a Best percentage change in tumor size from baseline, b tumor response by LOH and TMB scores. Patients without on-treatment target lesion measurements are not shown in Fig. 1a. Patients without response assessments are not shown in Fig. 1b. All response categories were determined according to RECIST 1.1 criteria. Full details of mutations can be found in Supplementary Table 5. CR complete response, LOH loss of heterozygosity, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease, TMB tumor mutational burden.
